Showing 1711-1720 of 2652 results for "".
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- SightLife Women Advocates Head to Nepal to Support Blindness Prevention Programhttps://modernod.com/news/sightlife-women-advocates-head-to-nepal-to-support-blindness-prevention-program/2479891/SightLife operates an innovative program in rural Nepal that is successfully preventing more than 125 cases of blindness each month, according to a company news release. In October, a group of women leaders in ophthalmology from around the US will visit Nepal to meet with health workers, p
- Alcon Launches New Multifocal Advertising Campaign to Increase Awareness of Contact Lens Optionshttps://modernod.com/news/alcon-launches-new-multifocal-advertising-campaign-to-increase-awareness-of-contact-lens-options/2480111/Alcon has launched its “See Near and Far” direct-to-consumer campaign to increase consumer awareness of multifocal contact lens options and encourage them to visit an eye care professional (ECP). The campaign will include a television spot that will run on ABC, NBC, CBS, and ESPN, among others, t
- Nation’s Ophthalmologists Remind Congress of the Importance of Medical and Surgical Eye Carehttps://modernod.com/news/nations-ophthalmologists-remind-congress-of-the-importance-of-medical-and-surgical-eye-care/2480227/More than 400 eye physicians and surgeons from across the United States are in Washington DC to urge Congress to preserve every patients’ access to quality medical and surgical eye care. As part of its annual visit to Capitol Hill, the
- Tenpoint Therapeutics Launches Yuvezzi Presbyopia Eye Drop in the UShttps://modernod.com/news/tenpoint-therapeutics-launches-yuvezzi-presbyopia-eye-drop-in-the-us/2486439/Key Takeaways Tenpoint Therapeutics has launched Yuvezzi, a once-daily prescription eye drop for adults with presbyopia, in the United States
- FDA Approves Yuvezzi, First Dual-Agent Eye Drop for Presbyopiahttps://modernod.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia/2485503/Tenpoint Therapeutics announced that the FDA has approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. Previously known as Brimochol PF, Yuvezzi is the first and only FDA-approved dual-agent
- Vision Expo 2026 Marks 40 Years With Expanded Education Experiencehttps://modernod.com/news/vision-expo-2026-marks-40-years-with-expanded-education-experience/2485286/Produced by RX and The Vision Council, Vision Expo is celebrating its 40th year in 2026 with an enhanced educational conference designed to deliver greater access, flexibility and real-world learning for vision care professionals.
- Nanoscope Announces 3-Year Vision Improvements from REMAIN Study of MCO-010 in RPhttps://modernod.com/news/nanoscope-announces-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2484207/Nanoscope Therapeutics announced 3-year follow-up data from the REMAIN study, the long-term extension of its pivotal phase 2b/3 RESTORE trial evaluating MCO-010, the company’s proprietary optogenetic therapy for retinitis pigmentosa (RP).
- Lumenis Launches Digital Duet 2.0 SLT+YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-20-sltyag-platform/2484200/Lumenis has unveiled Digital Duet 2.0, the latest evolution of its digital SLT+YAG platform for glaucoma and posterior capsulotomy treatment. The new system combines advanced imaging, seamless connectivity, and an enhanced user experience.
- Samsara Vision Launches PERSPECTIVE Trial, Achieves First Implant of SING IMT in Pseudophakic Patienthttps://modernod.com/news/samsara-vision-launches-perspective-trial-achieves-first-implant-of-sing-imt-in-pseudophakic-patient/2484154/Samsara Vision announced the initiation and successful first surgery of the PERSPECTIVE clinical trial. The study will evaluate the safety and efficacy of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in pseudophakic patients.